SK pharmteco vs WuXi Biologics: CDMO Comparison

Side-by-side comparison of SK pharmteco and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Signal Score
80/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
Available
Modalities
Viral Vectors, AAV, Lentiviral, Adenoviral, HPAPIs, Small Molecules, Peptides, BioCatalysis, Chromatography, Cell Therapy
Shanghai, CN · Wuxi, CN
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
—
Modalities
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody

Key differences

  • WuXi Biologics holds 3 active EMA GMP certificates; SK pharmteco does not appear in EudraGMDP.
  • WuXi Biologics maintains 1 MHRA / UK GMP certificate; SK pharmteco does not.

On a 13-modality CDMO landscape, both SK pharmteco and WuXi Biologics qualify as AAV manufacturers; WuXi Biologics carries the higher composite Signal Score for AAV programs in this comparison.

What to evaluate for AAV programs

Both SK pharmteco and WuXi Biologics qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

See all AAV CDMOs ranked by Signal Score →

Frequently asked: SK pharmteco vs WuXi Biologics

How do SK pharmteco and WuXi Biologics compare on European GMP coverage?

SK pharmteco holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is better for AAV manufacturing — SK pharmteco or WuXi Biologics?

Both SK pharmteco and WuXi Biologics are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

SK pharmteco carries a Signal Score of 80/100 and WuXi Biologics carries 84/100 — essentially tied for WuXi Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

How we score CDMOs →  ·  Compare other CDMOs →

Evaluating SK pharmteco and WuXi Biologics for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.